iRhythm Holdings, Inc.
IRTCHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, iRhythm Holdings, Inc. focuses on Medical Devices services and products. iRhythm Holdings, Inc. iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to. At a $4.00B market cap, iRhythm Holdings, Inc. ranks as a mid-cap company within healthcare. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.
Market Cap
$4.00B
Beta
1.46
P/E (TTM)
—
P/E (Fwd)
97.36
EPS (TTM)
$-0.42
EPS (Fwd)
$1.25
ROE
-9.6%
ROA
0.7%
Cash
$591.3M
Total Debt
$727.3M
Free CF
$81.8M
52W Change
-32.9%
Annual Financials
Cash vs Debt
Where IRTC stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, IRTC finished 5.91% below its 150-day moving average ($116.49) and 12.24% below its 200-day moving average ($124.88). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IRTC overbought or oversold?
At the October 20, 2026 close, IRTC's RSI(14) was 40.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
iRhythm Holdings, Inc. carries $727.3M in total debt against $591.3M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $81.8M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -9.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 0.7% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $410.9M (2022) to $747.1M (2025), reflecting a 82% increase over the period.
As with any equity investment, IRTC carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for iRhythm Holdings, Inc. and its sector.